Abstract Menorrhagia is one of the gynecological complaints, seen in women of reproductive age. In majority of cases no organic pathology is found. To date there is no consensus on application of von Willebrand disease (vWD) testing as part of the routine investigations in menorrhagia. Diagnosis of vWD is challenging. It is complicated by intraindividual variations in von Willebrand antigen, activity, and factor VIII levels due to fluctuation of these factor levels during the menstrual cycle or hormonal therapy. The aim of this study is to detect vWD presenting with menorrhagia among Malays attending gynecology clinic by using a standard panel of haemostatic profiles. Thirty Malay patients attending gynecology clinic with unexplained menorrhagia were included in this study. Haemostatic profile such as platelet count, prothrombin time, activated partial thromboplastin time (APTT), factor VIII assay, von Willebrand factor antigen, and von Willebrand factor activity, and collagen binding assay were measured in all patients. Pre-and post hormonal haemostatic profiles were also performed in the patients diagnosed as vWD. All patients had normal APTT. Based on von Willebrand factor work-up, vWD was diagnosed in four patients (13.3%). Three of them were Type 1 and the other one was Type 2M.
Introduction
Menorrhagia is one of the most common gynecological complaints, seen in women of reproductive age. In more than 50% of cases no organic pathology is found [1] . It has the risk from surgical procedure if it is not diagnosed early. Recently, there has been growing recognition that menorrhagia is a common manifestation for von Willebrand disease (vWD). Its prevalence was estimated from 5 to 20%, compared with less than 1% in women without menorrhagia [2] [3] [4] . To date there is no consensus on application of vWD testing as part of the routine investigations in patients presenting with menorrhagia.
Diagnosis of vWD is challenging and both human factors and laboratory limitations need to be considered together for the correct diagnosis. There are many factors contributing to the fluctuations of von Willebrand antigen and activity as well as factor VIII (FVIII) levels such as age (levels increased with age), race and ABO blood group (for O-group vWF levels generally lower than non-O blood group levels). Plasma von Willebrand factor (vWF) levels also fluctuate in individuals according to individual variation (different results are possible on sequential-day samples), diurnal variation (levels appear higher later in the day) and hormonal influenced (e.g., fluctuations within menstrual cycles, and higher levels in pregnancy) [5] .
Based on the heterogeneity in its manifestation and vWF multimer patterns, vWD is classified into Type 1, 2 and 3 with four subtypes for Type 2 (2A, 2B, 2N, 2M). Type 1 was the most frequent (60-80%) followed Type 2 variants (15-30%), and Type 3 seen in 5-10% of vWD patients [6] . Type 1 vWD is due to a quantitative deficiency of vWF, Type 2 is a qualitative defect. There are four subtypes of Type 2 which is classified as 2A, 2B, 2M, and 2N. Type 2B is associated with loss of high molecular weight (HMW) vWF multimers and mild thrombocytopenia. Type 2M variant shows decreased platelet function but it is not caused by a loss of HMW vWF Type 2N variant shows a markedly decreased affinity of vWF for FVIII. Type 3 vWD occurs when vWF is completely absent. To diagnose vWD, a reduction in either the level of vWF or its function must be detected in the patient.
Because of the assay limitations and vWD heterogeneity, no single laboratory procedure is able to detect all forms of vWD. Different combinations of test results will help to define the defect. Thus, our aim is to detect vWD in Malay patients presented with menorrhagia using a standard panel of haemostatic profiles.
Materials and methods
A cross-sectional study was conducted over a 1 year period at Hospital of Universiti Sains Malaysia (HUSM), Malaysia. The School of Medical Science Research and Ethical Committee had approved the protocol for this study. An informed written consent was given to all patients. Thirty Malay patients attended Gynecology clinic with history of unexplained menorrhagia were recruited.
ABO blood group, platelet count and haemostatic profile such as prothrombin time (PT), activated partial thromboplastin time (APTT) were performed as a screening assay. von Willebrand factor antigen (vWF:Ag) and von Willebrand factor activity (vWF:Ac) assay were performed by automated latex enhanced immunoassay (manufactured by IL) ( Table 1 , normal value). They were used to quantify and assess the function of vWF protein, respectively. Both assays were performed by the automated IL Coagulation Systems, ACL9000. In addition, collagen binding assay (vWF:CBA) (manufactured by Gradipore) using ELISA method was used as an additional method on the adhesive function of vWF protein. The normal range is 50-400%. When used in conjunction with the vWF:Ag assay, the CBA can be used to differentiate between vWD Type 1 and Type 2 by calculating a ratio of the two assay results as follows;
Ratio ¼ CBA% vWF:Ag FVIII assay and ristocetin induced platelet aggregation (RIPA) were measured in all patients to further subtype the disease using automated coagulation analyzer: ACL9000 and platelet aggregometer, Chronolog CA 500/560, respectively. Ratio for vWF:Ag/vWF:CBA, vWF:Ag/ FVIII:C, and or vWF:Ac/vWF:Ag were calculated and analyzed for all patients. Pre-and post hormonal haemostatic profiles were also performed on the patients diagnosed as vWD. However, multimer analysis and iron studies which can be used to assess the severity of menorrhagia were not done in these patients.
Statistical analysis
Data was entered into EPI Info 6.0 software and analyzed using the statistical package program, SPSS version 12.0 for windows. The statistical analysis used for comparison of the features between vWD and non-vWD were analyzes by Fisher-exact test and Independent t test. The effects of hormone therapy on von Willebrand results were analyzed by using Independent t test.
Results
Thirty Malay women aged between 17 and 52 years old were recruited from Gynecology clinic HUSM. The median age was 42 years old. They presented with history of menorrhagia for the duration ranging from 7 to 90 days. The onset of menorrhagia was less than 2 years in 43.3% of patient, 30% more than 2 years and 26.7% since menarche. Of 30 patients, 25 (83.3%) gave history of severe menorrhagia such as passing out blood clots during menses and 12 (40%) had other bleeding manifestations such as bruises, gum bleeds, epistaxis and prolonged bleeding after tooth extraction. No family history of consanguinity in these patients. All patients had normal platelet count and normal PT and APTT results ( Table 2) .
vWD was diagnosed in 4 of 30 (13.3%) Malay patients. They were older with mean age of 48.5 ± 4.5 years compared to non-vWF group, 38.2 ± 11.4 year old. No underlying local or systemic causes were obtained from these patients. Two of them had menorrhagia of less than The laboratory results between non-vWD and vWD were analyzed by using Independent t test. vWF:Ac and collagen binding assay (vWF:CBA) were significantly lower in patients with vWD compared to non-vWD, 55.4 (SD 7.4) versus 98.7 (SD 38.4) IU/dl (P value = 0.035) and 57.8 (SD 10.6) IU/dl versus 85.3 (SD 18.4) IU/dl (P value = 0.007), respectively. Hemoglobin, platelet count, PT, APTT, FVIII:C and vWF:Ag showed no significant difference in both group of women (Table 3) .
Discussion
vWD is an autosomal disorder and its prevalence is expected to be similar in men and women. However, women frequently are exposed to haemostatic challenges during menstruation as well as child birth, thus even the mildest form of vWD could be symptomatic. Menorrhagia is a common gynecologic problem and is a valuable predictor for an underlying congenital bleeding disorder.
The frequency of vWD in women with menorrhagia ranges from 5 to 20% in different studies [2] [3] [4] . The correct classification of vWD is important because they will differ accordingly to hemorrhagic risk and future management of patients. Currently there is no single test able to classify the disease and sometimes the diagnosis of vWD requires a follow-up for repeat testing.
Basic screening test in suspected cases is usually done by APTT test. However, APTT has limited value to screen for vWD. The availability of Platelet function analyzer for screening of the disease such as PFA-100 is not widely available in most laboratories. Complete tests including FVIII:C assay, vWF:Ag, vWF:Ac, vWF:ricof and vWF:CBA are important in the test panel for diagnosis of vWD. FVIII:C assay is used to determine the severity of vWD, to identify Type 2N vWD or hemophilia A. vWF:Ag could help to detect all Type 3 vWD, and identify most Type 1 but may miss many Type 2 patients. vWF:Ac and vWF:ricof measure the functional activity of vWF. Plasma from individuals with Type 2A, 2B, and usually 2M vWD will tend to give lower vWF:Ac results than vWF:Ag, due to the relative absence of HMW vWF (Type 2b), intermediate and HMW vWF (Type 2A), or functionally defective vWF (Type 2M). vWF:CBA also provides information on the function of vWF mainly on its adhesive quality. It was described to be more sensitive to the presence or absence of HMW vWF than vWF:Ac.
Panel for vWD used in this study was APTT, vWF:Ag, vWF:CBA, vWF:Ac, FVIII:C assay, and RIPA. If the results were abnormal, tests were to be repeated again. There was no difference between the initial and repeat results. From our study, 13.3% of women had menorrhagia. Its frequency in the Malay population was similar to the one reported in other populations. Further history inclusive the onset of menorrhagia, and other bleeding manifestations and laboratory screening assays (platelet count, PT and APTT) were not significantly different between women who were VWD and non-VWD. However, only vWF:Ac, and vWF:CBA exhibited a significant different between vWD and non-vWD (Table 2, 3) . Type 1 vWD was the commonest subtype (75%) detected in this study. Type 1 vWD is an autosomal dominant except Type 3 which is autosomal recessive. This is the reason why Type 3 is rarest and Type 1 is commonest among subtypes. The other patient was subtyped as 2M. In this patient, there was discordance between vWF:Ag and vWF:Ac and Type 2B has been excluded by RIPA (i.e. :no response at 0.5 mg/ml ristocetin or higher). She was classified as Type 2M vWD because the ratio of vWF:Ag/ vWF:Ac was greater than vWF:Ag/vWF:CBA. vWF:multimer analysis would be an option to differentiate Type 2A and 2M vWD [7] . Although the differentiation of this condition does not make much different in the management of patients, multimer analysis is still a necessity for accurate classification of vWD.
Patients diagnosed as vWD were then started on Tablet Marvelon, a combined oral contraceptive pill which contains desogestrel 150 lg and ethinyl estradiol 30 lg. Estrogen could raise the vWF level and FVIII level with subsequent decreased in bleeding episodes. There were an increased of vWF:Ag, vWF:Ac, vWF:CBA, and FVIII:C after they were started on tablet Marvelon although only the increment of collagen binding assay (vWF:CBA) was statistically significant in these patients. Screening for vWD in menorrhagia patients on hormonal treatment is not recommended as it will mask the haemostatic profiles and patients will be under-diagnosed. Subsequent surgical management if required in these patients will increase the risk of intra and post operative bleeding if vWD is not recognized.
From our study, mean for vWF: Ac and collagen binding assay (vWF:CBA) were significantly lower in patients diagnosed with vWD. This finding was similar with other study [8] . These tests may provide clinical relevance for women with menorrhagia who have normal APTT. Levels of vWF for antigenic assay were noted to be higher than the normal reference ranges in menorrhagic patients. This could be related to acute phase reaction to bleeding and thus the results of the investigation need to be interpreted with caution.
Screening for vWD is indicated in patients presenting with unexplained menorrhagia. In order for an accurate diagnosis, a complete panel of tests consisting of vWF:Ag, FVIII:C, vWF:Ac and collagen binding assay (vWF:CBA) are suggested for the initial vWD work-up, followed by RIPA for identification of vWD subtype. Screening for vWD should be performed before hormonal treatment as haemostatic profile post treatment would mask the diagnosis and carries a significant risk of morbidity should surgical intervention is required in the future management of these patients. 
